Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer. [electronic resource]
Producer: 20140514Description: 2390-6 p. digitalISSN:- 1569-8041
- Adenocarcinoma -- drug therapy
- Adult
- Aged
- Aged, 80 and over
- Albumins -- adverse effects
- Antineoplastic Agents, Phytogenic -- adverse effects
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Carboplatin -- adverse effects
- Carcinoma, Large Cell -- drug therapy
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Disease-Free Survival
- Female
- Humans
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Neoplasm Metastasis -- drug therapy
- Neoplasms, Squamous Cell -- drug therapy
- Organoplatinum Compounds -- adverse effects
- Paclitaxel -- adverse effects
- Survival
- Survival Rate
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.